Tissue plasminogen activator (TPA) can effectively treat patients with acute ischemic stroke, but only if administered within 3 h of stroke onset. This is not always feasible, because patients often ...

Intravenous recombinant tissue plasminogen activator can be used for the treatment of acute ischemic stroke in the elderly (age ≥80 years) within the NINDS rtPA protocol The study was a prospective ...

May 28, 2009 — A new science advisory from the American Heart Association (AHA)/American Stroke Association (ASA) has given the green light to the use of tissue plasminogen activator (tPA) to treat ...

Adult patients with sickle cell disease (SCD) who experience a stroke caused by a clot (i.e., ischemic strokes or IS) can be treated safely with tissue plasminogen activator (tPA) if they qualify, ...

In the largest report on acute stroke in sickle cell disease to date, researchers at the Medical University of South Carolina and elsewhere provide the first systemic evidence for the safe use of tPA ...

All potential acute ischemic stroke patients meeting criteria for the use of IV tPA should be offered treatment. The facts are clear, and all that remains is further provider and patient education.

Patients suffering from a stroke are more likely to have improved outcomes and fewer complications when hospitals use standardized guidelines for stroke care during a patient’s admission and discharge ...

Among patients presenting directly to a thrombectomy-equipped center with a large-vessel ischemic stroke, going directly to the endovascular suite and forgoing initial IV thrombolytic therapy provides ...